Dog Bladder Cancer: Symptoms, Diagnosis, and Treatment Options

When a dog strains to urinate or produces bloody urine, owners often suspect a simple urinary tract infection (UTI). However, these same signs can also signal a more serious, yet uncommon, condition: bladder cancer. Prompt veterinary evaluation is essential, whether the cause is a UTI or a malignant tumor.

Below, we provide a comprehensive guide to help pet owners recognize, diagnose, and manage bladder cancer in dogs.

Dog Bladder Cancer: Prevalence and Types

The most frequently encountered bladder cancer in dogs is transitional cell carcinoma (TCC), also known as urothelial carcinoma. TCC originates from the transitional epithelial cells lining the bladder and upper urethra. It typically arises in the bladder neck—near the ureteral and urethral openings—making surgical removal challenging. In many cases, the urethra is also involved.

Other, less common bladder tumors include rhabdomyosarcoma and leiomyosarcoma (the latter, malignant or benign, accounts for about 12% of primary bladder tumors). Rhabdomyosarcomas are rare and tend to appear in younger dogs.

Bladder cancer represents fewer than 2% of all canine cancers. TCC alone comprises 70–80% of bladder tumors. Middle‑aged to senior, small‑breed dogs—especially Scottish Terriers, West Highland White Terriers, Beagles, and Shetland Sheepdogs—are most at risk. Scottish Terriers are 18–20 times more likely to develop TCC than other breeds, with an average diagnosis age of 11 years.

Although veterinarians rarely stage canine bladder cancer formally, they assess for local invasion and distant metastasis to lymph nodes, lungs, and bone, which is crucial for treatment planning.

Causes and Risk Factors

In many cases, no clear cause is identified, but genetics play a significant role, especially in predisposed breeds. Female dogs experience TCC more frequently, possibly due to longer urine retention and exposure to urinary carcinogens. Rare associations include cyclophosphamide chemotherapy and phenoxy herbicide–treated lawns; chronic exposure to hydrocarbons such as cigarette smoke may also increase risk. Leiomyosarcoma and rhabdomyosarcoma are typically idiopathic.

Clinical Signs

Bladder cancer can mimic common conditions like UTIs and bladder stones. The most frequent symptoms are:

• Frequent, small-volume urination (pollakiuria)
• Blood in the urine (hematuria)
• Straining to urinate (stranguria)

Additional, less common signs include:

• Straining to defecate (tenesmus)
• Abdominal pain or distension
• Hypertrophic osteopathy—a rare bone proliferation that causes limping, often requiring pain management and tumor control

While these signs are common to many urinary disorders, persistent or recurrent symptoms after antibiotic treatment should prompt a thorough evaluation for bladder cancer.

Diagnostic Approach

A comprehensive diagnostic plan typically includes:

• Urinalysis with culture to detect UTIs and identify antibiotic sensitivities.
• Radiographs (X‑rays) to rule out bladder stones and assess urinary tract anatomy.
• Abdominal ultrasound, the most sensitive imaging for detecting bladder masses and evaluating potential metastasis.
• Chest X‑rays to screen for pulmonary spread.

When imaging suggests a bladder mass—especially in the neck of the bladder—a presumptive diagnosis of TCC can be made. Definitive confirmation requires cytology or histopathology. Fine‑needle aspiration (FNA) is generally avoided for suspected TCC due to the risk of tumor seeding.

Alternative sampling methods include cystotomy (surgical biopsy) or traumatic catheterization, which dislodges tumor cells into the urine. Advanced referral centers may offer cystoscopy, allowing direct visualization and biopsy via a urethral camera. The BRAF mutation test, performed on urine, detects TCC‑specific genetic alterations and can identify tumors before imaging shows them. When combined with the BRAF‑PLUS test, detection accuracy reaches 95%.

Treatment Options

Because TCC commonly arises near critical structures, curative surgery is rarely feasible. Most treatment goals focus on palliative care and quality‑of‑life maintenance.

• Medical therapy: NSAIDs with antitumor activity (piroxicam, deracoxib, firocoxib) are the mainstay, often combined with chemotherapy agents such as mitoxantrone, carboplatin, vinblastine, or cisplatin. Response rates reach ~40%, with tumors shrinking or slowing growth.
• Radiation therapy: Modern, targeted protocols can effectively control local disease but require specialized centers and may necessitate travel.
• Supportive procedures: Urethral stenting may relieve obstruction; permanent urinary catheters provide drainage but increase infection risk and caregiving demands.
• Extirpative surgery: Bladder removal (cystectomy) is rarely pursued due to high morbidity, potential complications, and limited impact on metastatic disease.

Regardless of the chosen modality, owners should anticipate regular follow‑ups, urine cultures, bloodwork, and imaging to monitor treatment efficacy and detect recurrence or spread.

Cost Considerations

Conservative NSAID therapy costs roughly $25–$75 monthly, excluding monitoring. Comprehensive referral care—including diagnostics, chemotherapy, radiation, and supportive devices—can exceed $10,000. Participation in clinical trials or university‑based studies may reduce expenses and contribute to advancing canine oncology.

Prognosis

TCC is locally aggressive and prone to metastasis. With NSAID therapy alone, median survival is ~6 months; adding chemotherapy extends it to 9–11 months, though outcomes vary with age, tumor burden, and metastatic spread. The primary goal remains to preserve quality of life.

Preventive Measures

While a definitive prevention strategy is elusive, owners of at‑risk breeds can adopt the following practices:

• Provide leafy greens and citrus‑rich foods (yellow/orange) at least three times per week.
• Avoid older flea control products (e.g., flea dips) and reduce exposure to herbicide‑treated lawns.
• Limit secondhand smoke exposure.
• Maintain a healthy weight.

Regular BRAF testing in predisposed breeds may detect early disease before clinical signs appear. Veterinary support teams can offer counseling and connect families to resources during difficult times.